

ASX ANNOUNCEMENT

22 November 2022

Results of Annual General Meeting

Melbourne, Australia; 22 November 2022: Cynata Therapeutics Limited (ASX: “CYP”, “Cynata”, or the “Company”), advises that its Annual General Meeting of Shareholders was held today at 11.30 am AEDT.

In accordance with Listing Rule 3.13.2 and section 251AA(2) of the Corporations Act 2001 (Cth), the Company advises that the details of the resolutions and the proxies received in respect of each resolution are set out in the attached proxy summary.

-ENDS-

Authorised for release by Dr Ross Macdonald, Managing Director & CEO

CONTACTS: Dr Ross Macdonald, CEO, Cynata Therapeutics, +61 (0)412 119 343, ross.macdonald@cynata.com
Lauren Nowak, Media Contact, +61 (0)400 434 299, littlebigdealconsulting@gmail.com

About the Clinical Trial

The clinical trial, entitled “Safety and Efficacy of iPSC-derived Mesenchymal Stromal Cell Therapy in Renal Transplant Recipients – the Nereid Study”, is an open label, non-randomized, non-blinded, prospective, single centre clinical phase Ib study. It will be conducted in 10 renal allograft recipients, aged 18-75 years old. The principal investigator is Dr. HS Spijker, Department of Nephrology, LUMC. Following their transplant surgery, patients will receive a drug used to treat graft rejection and two doses of Cymerus MSCs 6 and 7 weeks after transplantation followed by withdrawal of anti-rejection medication. The primary end point is safety by assessing absence of acute rejection (absence of graft loss after 6 months) after withdrawal of anti-rejection medication. Other end points include assessment of renal function at 6 months and the incidence of opportunistic infections.

About Cynata Therapeutics (ASX: CYP)

Cynata Therapeutics Limited (ASX: CYP) is an Australian clinical-stage stem cell and regenerative medicine company focused on the development of therapies based on Cymerus™, a proprietary therapeutic stem cell platform technology. Cymerus™ overcomes the challenges of other production methods by using induced pluripotent stem cells (iPSCs) and a precursor cell known as mesenchymoangioblast (MCA) to achieve economic manufacture of cell therapy products, including mesenchymal stem cells (MSCs), at commercial scale without the limitation of multiple donors.

Cynata’s lead product candidate CYP-001 met all clinical endpoints and demonstrated positive safety and efficacy data for the treatment of steroid-resistant acute graft-versus-host disease (GvHD) in a Phase 1 trial. Planning for a Phase 2 clinical trial in GvHD under a cleared US FDA IND is presently underway. Clinical trials of Cymerus products in osteoarthritis (Phase 3) and diabetic foot ulcers (DFU) are currently ongoing. In addition, Cynata has demonstrated utility of its Cymerus technology in preclinical models of numerous diseases, including the clinical targets mentioned above, as well as critical limb ischaemia, idiopathic pulmonary fibrosis, asthma, heart attack, sepsis, acute respiratory distress syndrome (ARDS) and cytokine release syndrome.

Cynata Therapeutics encourages all current investors to go paperless by registering their details with the designated registry service provider, Automic Group.

Disclosure of Proxy Votes

Cynata Therapeutics Limited

Annual General Meeting

Tuesday, 22 November 2022



Automic

GPO Box 5193, Sydney, NSW 2001

P 1300 288 664 (aus) or +61 (0)2 9698 5414 (world)

F +61 (0)2 8583 3040 E hello@automic.com.au

ABN 27 152 260 814

In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to members at the meeting.

Resolution	Decided by Show of Hands (S) or Poll (P)	Total Number of Proxy Votes exercisable by proxies validly appointed	Proxy Votes				Poll Results (if applicable)		
			FOR	AGAINST	ABSTAIN	PROXY'S DISCRETION	FOR	AGAINST	ABSTAIN
1 Adoption of Remuneration Report	P	47,409,127	44,338,807 93.52%	2,035,824 4.29%	152,525	1,034,496 2.18%	44,157,185 89.85%	4,985,556 10.15%	232,525
2 Re-election of Dr Geoff Brooke as a Director	P	40,004,233	37,885,848 94.70%	1,031,252 2.58%	12,948,057	1,087,133 2.72%	40,186,595 97.50%	1,031,252 2.50%	13,548,057
3 Re-election of Ms Janine Rolfe as a Director	P	52,744,217	50,807,624 96.33%	849,460 1.61%	208,073	1,087,133 2.06%	53,708,371 98.44%	849,460 1.56%	208,073
4 Approval of 10% Placement Facility	P	52,922,909	49,407,071 93.36%	2,364,415 4.47%	29,381	1,151,423 2.18%	49,342,376 91.53%	4,564,137 8.47%	859,391
5 Approval of issue of Director Options to Ms Janine Rolfe	P	52,744,505	49,501,549 93.85%	2,101,623 3.98%	207,785	1,141,333 2.16%	52,226,486 96.13%	2,101,623 3.87%	437,795
6 Approval of amendments to the Constitution	P	52,653,354	36,806,367 69.90%	14,641,154 27.81%	298,936	1,205,833 2.29%	39,225,814 72.02%	15,241,154 27.98%	298,936

